apollomics

# INVESTOR PRESENTATION

September 2022

# Legal Disclaimer

### Important Information for Investors

This investor presentation (this "Presentation") (references to which shall be deemed to include any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further enquiries) relates to a proposed business combination (the "Transaction") between Maxpro Capital Acquisition Corp. ("Maxpro") and Apollomics Inc. (together with its subsidiaries and affiliates, "Apollomics"). This Presentation does not contain all of the information that should be considered with respect to the proposed Transaction. This Presentation is for informational purposes only and is not intended to form any basis of any investment decision or any other decision in respect of the proposed Transaction. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein.

### Confidentiality

By its acceptance hereof, each recipient agrees that neither it, its affiliates nor their respective agents, partners, directors, accountants, counsel, officers, employees or other representatives (collectively, "Representatives") will copy, reproduce or distribute to others this Presentation, in whole or in part, at any time without the prior written consent of Apollomics and Maxpro and that it will keep confidential all information contained herein not already in the public domain and will use this Presentation for the sole purpose of deciding whether to proceed with a further investigation of Apollomics or the Transaction. The recipient shall be responsible for any violation of obligations by any of its Representatives.

#### Industry and Market Data

The views and statements provided in this Presentation are based on information derived from Apollomics' internal estimates and research, studies, publications, surveys and other information provided by third parties and also from publicly available sources. In this Presentation, Apollomics and Maxpro rely on, and refer to, publicly available information and statistics regarding market participants in the sector in which Apollomics competes and other industry data. Any comparison of Apollomics to any other entity assumes the reliability of the information available to Apollomics. Neither Apollomics nor Maxpro has independently verified the accuracy or completeness of these sources.

### Cautionary Language Regarding Forward Looking Statements

This Presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "goal," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Apollomics' and Maxpro's expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: plans for preclinical studies, clinical trials and research and development programs; the anticipated timing of the results from those studies and trials; expectations regarding regulatory approvals; Apollomics' and Maxpro's expectations with respect to future performance and anticipated financial impacts of the Transaction; the satisfaction of the closing conditions to the Transaction; and the timing of the completion of the Transaction. Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by Apollomics and its management, and Maxpro and its management, as the case may be, are inherently uncertain. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of Apollomics' and Maxpro's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Apollomics and Maxpro.

These forward-looking statements are subject to a number of risks and uncertainties, including (i) changes in domestic and foreign business, market, financial, political and legal conditions; (ii) the inability of the parties to successfully or timely consummate the Transaction, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the Transaction or that the approval of the shareholders of Maxpro is not obtained; (iii) failure to realize the anticipated benefits of the Transaction; (iv) risks relating to the uncertainty of the projected financial information with respect to Apollomics; (v) future global, regional or local economic and market conditions; (vi) the development, effects and enforcement of laws and regulations; (vii) Apollomics' ability to manage future growth; (viii) changes in the market for Apollomics' products and services; (ix) the amount of redemption requests made by Maxpro's public stockholders; (x) the ability of Apollomics or the combined company to issue equity or equity-linked securities in connection with the Transaction or in the future; (xi) the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries that may be instituted against Maxpro, Apollomics, the combined company or others following the announcement of the Transaction and any definitive agreements with respect thereto; (xii) the occurrence of any event, change or other circumstance that could give rise to the termination of the Business Combination Agreement with respect to the Transaction or the inability of Maxpro or Apollomics to satisfy the conditions to closing the Transaction; (xiii) changes to the proposed structure of the Transaction that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Transaction; (xiv) the ability to meet stock exchange listing standards following the consummation of the Transaction; (xv) the risk that the pendency of the Transaction or time required to consummate the Transaction disrupts current plans and operations of Apollomics; (xvi) the evolution of the market in which Apollomics operates; (xvii) the ability of Apollomics to commercialize product candidates and achieve market acceptance of such product candidates; (xviii) the ability of Apollomics to defend its intellectual property; (xix) the ability of Apollomics to satisfy regulatory requirements; (xx) other risks and uncertainties included in the Current Report on Form 8-K filed by Maxpro with the United States Securities and Exchange Commission (the "SEC") concurrently with this Presentation; and (xxi) those factors discussed in Maxpro's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 31, 2022 under the heading "Risk Factors," and other documents of Maxpro and Apollomics filed, or to be filed, with the SEC. If any of these risks materialize or Maxpro's or Apollomics' assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither Maxpro nor Apollomics presently know or that Maxpro and Apollomics currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Maxpro's and Apollomics' expectations, plans or forecasts of future events and views as of the date of this Presentation. Maxpro and Apollomics anticipate that subsequent events and developments will cause Maxpro's and Apollomics' assessments to change. However, while Maxpro and Apollomics may elect to update these forward-looking statements at some point in the future, Maxpro and Apollomics specifically disclaim any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Maxpro's and Apollomics' assessments as of any date subsequent to the date of this Presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements.

# Legal Disclaimer (contd.)

### No Representations and Warranties

No representation, warranty or undertaking, express or implied, is made or will be given by Apollomics, Maxpro and their respective affiliates and Representatives as to the fairness, accuracy, completeness or reliability of this Presentation and the information and or statements contained therein. Any recipient of this Presentation is responsible for conducting his or her own due diligence and other enquiries as well as making his or her own analysis and his or her own independent assessment of the information provided herein in connection with the Transaction. Any decision to rely on the information contained in this Presentation is the sole responsibility of the recipient of this document and neither Apollomics nor Maxpro will be responsible for any loss incurred by the recipient as a result of any actions taken by him or her relying upon the information herein. This Presentation is based, in part, upon management estimates and forecasts of Apollomics and reflects views and opinions solely of Apollomics as of the date of this Presentation, all of which are accordingly subject to change. Any such estimates, forecasts, views or opinions set forth in this Presentation constitute Apollomics' judgments and should be regarded as indicative, preliminary and for illustrative purposes only. In addition, Apollomics' analyses contained herein are not, and do not purport to be, appraisals of the issued share capital, assets or business of Apollomics, Maxpro or any other entity. Further, this Presentation does not purport to contain all information that may be required or relevant to an evaluation of the Transaction.

### No Offer or Solicitation

This Presentation does not constitute an offer, or a solicitation of an offer, to buy or sell any securities, investment or other specific product, or a solicitation of any vote or approval, nor shall there be any sale of securities, investment or other specific product in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any securities to be offered in any transaction contemplated hereby have not been approved or disapproved by the SEC, any state securities commission or other United States or foreign regulatory authority,and will be offered and sold solely in reliance on an exemption from the registration requirements provided by the Securities Act and rules and regulations promulgated thereunder (including Regulation D or Regulation S under the Securities Act). This document does not constitute, or form a part of, an offer to sell or the solicitation of an offer to buy in any state or other jurisdiction to any person to whom it is unlawful to make such offer or solicitation. Consequently, this Presentation does not contain all the information which would be required to be contained in such a prospectus or disclosure document such as, for example, details of the assets and liabilities, financial position, profits and losses and prospects of any of the entities referred to in this Presentation. The material provided in this Presentation is provided for the information of recipients and does not constitute an invitation or inducement to such persons to enter any investment activity relating to those entities. Apollomics and Maxpro have not considered the objectives, financial position or needs of any recipient. The recipient should obtain and rely upon his or her own professional advice from their tax, legal, accounting, financial and other professional advisors in respect of the recipient's objectives, financial position or needs before making any investment decision based on information contained in this Presentation.

Neither this Presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of Apollomics and Maxpro. In accepting this Presentation, the recipient agrees that it is provided solely for its use in connection with providing background information on Apollomics and considering the Transaction and that it is not to be used for any other purpose. Should a security described in this Presentation be denominated in a currency other than the recipient's home currency, a change in exchange rates may adversely affect the price of, value of, or income derived from the security. Neither this Presentation nor any of its contents is represented to comply with nor is to be construed to comply with any of the legal requirements in any jurisdiction in respect of an offer to buy or sell or a solicitation of an offer to buy or sell securities.

### Participants in the Solicitation

Maxpro, Apollomics and their respective directors and executive officers may be deemed under SEC rules to be participants in the solicitation of proxies of Maxpro's stockholders in connection with the Transaction. Investors and security holders may obtain more detailed information regarding the names and interests of Maxpro's directors and officers in the Transaction in Maxpro's filings with the SEC, including Maxpro's Annual Report. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of Maxpro's stockholders in connection with the Transaction will be set forth in the proxy statement/prospectus contained in the registration statement on Form F-4 for the Transaction.

#### Trademarks and Copyrights

This Presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and Apollomics' and Maxpro's use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks, service marks, trade names and copyrights. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this Presentation may be listed without the TM, © or ® symbols, but Apollomics and Maxpro will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.

All images are copyright to their respective owners and are protected under international copyright laws.

### Additional Information and Where to Find It

Apollomics intends to file with the SEC a registration statement on Form F-4 that will include a preliminary proxy statement/prospectus to be distributed to stockholders of Maxpro in connection with Maxpro's solicitation of proxies for the vote by its stockholders with respect to the Transaction. After the registration statement has been filed and declared effective by the SEC, Maxpro will mail the definitive proxy statement/prospectus to all Maxpro stockholders as of a record date to be established for voting on the Transaction and other matters as may be described in the registration statement. Maxpro and Apollomics also will file other documents regarding the Transaction with the SEC. Before making any voting decision, investors and security holders of Maxpro are urged to carefully read the entire registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC, as well as any amendments or supplements to these documents, in connection with the Transaction as they become available because they will contain important information about the proposed Transaction. Investors and security holders will be able to obtain free copies of the registration statement, proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Maxpro or Apollomics through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by Maxpro may be obtained free of charge by written request to Maxpro at 5/F-4, No. 89, Songren Road, Xinyi District, Taipei City, Taiwan 11073, Attention: Secretary, telephone: +886 2 7713 7952, and the documents filed by Apollomics may be obtained free of charge by written request to Apollomics at 989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404, Attention: Secretary.

# Transaction Highlights

**deSPAC TRANSACTION**

- Apollomics Inc. (“Apollomics”) and Maxpro Capital Acquisition Corp. ("JMAC") have entered into a definitive business combination agreement
- Transaction values Apollomics at $899M
- Transaction expected to close in the first quarter of 2023
- 100% rollover from legacy Apollomics shareholders
- $105.05M in total estimated proceeds in JMAC trust (assuming no redemptions)
- $20M minimum cash condition

**USE OF PROCEEDS**

- Provide funding for Vebreltinib (APL-101) through ongoing registrational Phase 2 clinical trials in the US, 1 NDA filing and 2 sNDA filings
- Provide funding for APL-106 (Uproleselan) Phase 3 and NDA filing in China
- Continue pipeline development and discovery projects

# Transaction Details

## SOURCES ($M)

| Redemption Rate Assumption | 0% | MAXIMUM |
|---|---|---|
| Apollomics Shareholder Equity Rollover [1] | $899.0 | $899.0 |
| JMAC Cash in Trust | 105.1 | 20.0 |
| Total Sources | $1,004.1 | $919.0 |

## USES ($M)

| Redemption Rate Assumption | 0% | MAXIMUM |
|---|---|---|
| Equity Issued to Apollomics Shareholders [1] | $899.0 | $899.0 |
| Cash to Company Balance Sheet | 100.2 | 15.1 |
| Estimated Transaction Costs [4] | 4.9 | 4.9 |
| Total Uses | $1,004.1 | $919.0 |

## PRO FORMA CAPITALIZATION (M Shares, %)

| Redemption Rate Assumption | 0% | | MAXIMUM | |
|---|---|---|---|---|
| Apollomics Shareholder Equity Rollover [1] | 89.9 | 87.0% | 89.9 | 94.7% |
| JMAC public shareholders [2] | 10.4 | 10.0% | 2.0 | 2.1% |
| JMAC promote [3] | 2.6 | 2.5% | 2.6 | 2.7% |
| JMAC private placement | 0.5 | 0.5% | 0.5 | 0.5% |
| JMAC underwriter shares | 0.0 | 0.0% | 0.0 | 0.0% |
| Total outstanding shares with vested options | 103.3 | 100.0% | 94.9 | 100.0% |

1. Capitalization calculated on a net-exercise basis: 89.90M shares to Apollomics shareholders and vested option holders are net of exercise proceeds for pre-closing vested options; assumes $10 price per JMAC share; excludes JMAC public and private placement warrants.
2. The illustrative maximum redemption scenario represents the approximate maximum number of JMAC public shares that may be redeemed while meeting the $20M minimum cash condition, or approximately 81% redemptions at a redemption price of $10.15 per share. Actual redemptions may vary and may be significant.
3. Sponsor promote may be reduced if Sponsor shareholdings exceed 2.75% of total outstanding shares and vested option shares at closing.
4. Excludes fees paid before the closing or from the Company's existing cash on hand.

# Apollomics: On a mission to discover ways to treat cancer

1. Innovative clinical-stage biotechnology company focused on discovering and developing oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer
2. Pipeline of nine drug candidates across multiple oncology programs
3. Six drug candidates are in the clinical stage
4. Focused on the development of novel therapies targeting difficult to treat cancers with high mortality rates




**2016** — OrbiMed ~$10M Series A

**2018** — Series B $99M

**2020** — GlycoMimetics partnership for Uproleselan
Series C ~$124M

**2021** — TYG partnership for Gastrin 17 ("G17") vaccine
Edison Oncology partnership for pan-ErbB inhibitor

**2022** — Entry into deSPAC transaction with JMAC

# Maxpro Capital Acquisition Corp. Overview

- Maxpro Capital Acquisition Corp. (Nasdaq: JMAC) is a publicly listed special purpose acquisition company that completed a $105.05M IPO on October 13, 2021
- JMAC is sponsored by MP One Investment LLC, established by Maxpro Capital Ventures, a healthcare private equity fund
- Maxpro has deep insight and knowledge of the healthcare sector, with extensive experience working with and advising clinical-stage biotechnology companies
- Possesses strong network of biotech professionals and industry experts
- Professional management team with M&A expertise in capital markets

JMAC

# Seasoned Executives at Apollomics

Guo-Liang Yu
PhD
Co-founder
Chairman and CEO

**Serial Entrepreneur**

- Founder of Epitomics; Executive Chairman of Crown Bioscience
- 30+ years experience
- 300+ patents; 30+ publications
- U.C. Berkeley, Harvard, Human Genome Sciences

Sanjeev Redkar
PhD, MBA
President &
Co-founder

- 28 years in oncology drug development
- 5 NDAs, 5 NCEs and 15 INDs/CTAs in previous roles
- Matrix Pharmaceuticals, SuperGen, Astex, Otsukaa

Kin-Hung Peony Yu
MD,
Chief Medical Officer

- 20+ years in global clinical development leadership: IND, Phase 1, 2, 3, and 4 studies
- Multiple successful NDAs in US, China, Japan, and MAAs in EU in prior roles - Stanford, FibroGen, Anesiva, J&J, Elan

Jane Wang
PhD
Chief Scientific Officer

- 20 years in drug discovery
- Focus in oncology, inflammation, and CNS
- 60 patents and 29 publications in prior roles
- Pfizer, NIH, Schering Plough, Wuxi

Brianna McDonald
JD
VP & General Counsel

- 15 years' experience
- Stanford University, BA
- Harvard Law School, JD
- Covington & Burling LLP, Google LLC, Verily Life Sciences LLC

Raymond Low
CPA,
VP Finance,
Corporate Controller

- 22 years' experience
- B Com University of South Africa, CMA England
- Rstar, Therasense, AXT, Sciclone Pharmaceuticals

# Seasoned Executives at JMAC

Moses Chen
JMAC CEO

## Senior Executive

- Managing Director of Maxpro Ventures Ltd. since May 2018
- 20+ years of academic and biotech experience
- Rutgers, Caltech, VivoRx, AmCyte, Celgene, Meridigen, SyneuRx

Gau, Wey – Chuan (Albert)
JMAC CFO

## Senior Executive

- Consultant at KPMG in Taiwan since February 2021
- Provided audit and tax services for KPMG international and local public clients for 30 years
- Provided consultancy services for IPO, domestic and overseas fund raising, financial and tax planning

# Growth: From Discovery to Clinical towards Commercial

## 2016 – 2018
### Foundation Established

- Series A OrbiMed
- Phase 1 in US for APL-101
- Phase 1 in Australia for APL- 501
- Clinical team in US

## 2019 – 2022
### Gained Momentum

- Series B and Series C
- APL-101:
  - Phase 1 completed
  - Global Phase 2
  - Registration path in US
- APL-106:
  - Phase 1 initiated in China
  - Phase 3 initiated in China
- APL-122, APL-102 FPI

## 2023 – 2025
### Transformative Goals

- APL-101 (US-Global)*:
  - NDA NSCLC ex14 skip
  - sNDA NSCLC c-MET
  - sNDA GBM c-MET fusion
- APL-106 (China)**:
  - NDA r/r AML
  - sNDA in t/n AML
- Commercial partnerships
- Expand discovery group in Hangzhou

*Assuming successful APL-101 Phase II clinical trials and/or results of Phase III clinical trials available and supportive for the anticipated NDA/sNDA

**Assuming results of APL-106 Phase III clinical trials available and supportive for an NDA/sNDA

# Our Pipeline

| | Drug Candidate | Target | Category | IP Rights | Mono / Combo | Indications | Status |
|---|---|---|---|---|---|---|---|
| Tumor Inhibitors | ★APL-101 Vebreltinib | c-Met | Small molecule | Global [1] | Mono | NSCLC, GBM, other solid tumors | |
| | APL-122 | ErbB1/2/4 | Small molecule | Global [2] | Mono | ErbB1/2/4 positive cancers | |
| | APL-102 | Multiple Kinases | Small molecule | Global | Mono | Solid tumors | |
| Anti-Cancer Enhancers | ★APL-106 | E-Selectin | Small molecule | China | + Chemo | r/r AML, newly diagnosed AML | |
| | APL-108 | E-Selectin | Small molecule | China | + Chemo | MM | By GlycoMimetics in the U.S. |
| Immuno-oncology Drugs | APL-501 | PD-1 | Biologic | Global [3] | Mono | Solid tumors | |
| | APL-502 | PD-L1 | Biologic | Global [3] | Mono | Multiple tumor types | |
| | APL-810 | G17-neutralization | Biologic | US, China | Mono | Gastrointestinal (GI) cancers | |
| | APL-801 | CD40 and PD-L1 | Biologic | Global | Mono | Multiple tumor types | |

Status: Discovery | Preclinical | IND | Phase 1 | Phase 2 | Phase 3 | NDA

★ **Core Programs**

**Apollomics Trials**

**Partner Trials**

# Vebreltinib (APL-101) c-Met TKI
# ~ $10B market opportunity in NSCLC With c-MET Dysregulation

## NSCLC



**188,000 US incidence***
**1.8 million worldwide***

## $3B market opportunity**

c-Met dysregulated Non-Small Cell Lung Cancer ("NSCLC") population

- Exon-14 skip mutation (1L, 2L) — **~ 6,300 patients***
- c-Met amplifications, denovo — **~ 2,500 patients*****
- c-Met amplifications, resistance driven — **~ 3,100 patients*****

## $7B market opportunity**

Epidermal Growth Factor Receptor (EGFR) mutated NSCLC population

- 1L EGFR+ in combination with osimertinib — **~ 20,700 patients***

Source: * Biomedtracker
** Management estimates for the US market for 2022 calculated by multiplying number of patients with an estimated drug price
*** Management estimates based on prevalence from Drillon et al 2016 - Targeting MET in Lung Cancer mentions and prevalence of NSCLC from Biomedtracker

# Regulatory Landscape of c-MET inhibitors TKI

## *Approved c-MET inhibitor TKIs*

| Agent* | Manufacturer(s) | MOA | Line of Therapy* | Biomarker (NGS) | U.S. FDA Approval | EU5 EMA Approval | JP MHLW Approval | CN NMPA Approval |
|---|---|---|---|---|---|---|---|---|
| **Patients with MET mutations** | | | | | | | | |
| **Orpathys®** *(savolitinib)* | HutchMed and AstraZeneca (CN) | MET inhibitor | Relapsed / refractory or 1L, chemotherapy ineligible | NSCLC w/ MET Ex14 skipping | None | None | None | Jun-21 (conditional) |
| **Tabrecta®** *(capmatinib)* | Novartis (U.S., EU5, JP) | MET inhibitor | 1L | NSCLC w/ MET Ex14 skipping | May-20 (accel) Aug-22 (full) | June-22 | Jun-20 | None |
| **Tepmetko®** *(tepotinib)* | Merck KGaA (U.S., JP) | MET inhibitor | Unresectable advanced / recurrent | NSCLC w/ MET Ex14 skipping | Feb-21 (accel) | Dec-21 | Mar-20 (conditional) | None |

**Estimated US Pricing****:

| | | | |
|---|---|---|---|
| Tabrecta | 400mg BID | 150mg, 200mg/ 56 tabs ($11K) | $22K/mo |
| Tepmetko | 450mg QD | 225mg/ 30 tabs ($11k) | $22k/mo |

- mAb = monoclonal antibody; mono = monotherapy; + = combination with; accel = accelerated approval; cond = conditional approval.
  *These approvals are current as of the date of publication of this report and stated line of therapy is an approximation if not explicitly stated in the regulatory label; please refer to official product labels for most current approval status and nuanced description of the approved indications by market.
  ** Management's estimates based on public information on Drugs.com

# Vebreltinib: 3 Indications for near term NDA/sNDA submissions




## Vebreltinib

***Global Multicohort Phase 2 – Non-Small Cell Lung cancer, Glioblastoma ("GBM"), various solid tumors with c-Met dysregulation***

- ✓ Highly specific c-Met inhibitor
- ✓ Brain penetration
- ✓ Safety data available from over 370 patients worldwide

- ✓ Biomarkers to target c-Met patients
- ✓ Strong IP with 7 patents awarded covering the compound

- ✓ Orphan drug designation by FDA
- ✓ ~ 140 patients treated in Apollomics SPARTA trial ongoing in 13 countries and 90+ sites
- ✓ Registrational Phase 2 study in NSCLC with exon 14 skip or c-Met amplification (China)
- ✓ Phase 2/3 GBM with PTPRZ1-MET fusion (China)

- ✓ Potential combo therapy w/EGFR inhibitors, etc., with huge potential
- ✓ Potential other tumors: Gastrointestinal, renal, thyroid, etc.

# Activity in a Patient with Primary NSCLC Lesions and Brain Metastasis

*NSCLC with c-Met amplification*




Source: Yilong Wu et al, Presentation on Phase 1 Open Investigation of the Safety and Tolerability of Bozitinib Enteric Capsules in Late-Stage NSCLC with c-Met Amplification (NCT02896231/CTONG160), at the Annual Conference of Chinese Society of Clinical Oncology in 2019

# Activity in a Glioblastoma Patient with c-MET Amplification

## *On treatment for 2+Years*

- 78-yr old female, GBM since May 2015, c-Met Amplification, target lesion Lt Subependymal
- Received 3 prior lines of therapies (Temodar 2015-2017, Avastin 2017-2018, Nivolumab 2018-2019)
- C1D1: 04Sep2019;  2+ yr treatment, durable response

| Visit | Product of Perpendicular Diameters |
|---|---|
| **Screening** | **285** |
| Cycle 3 Day 1 | 285 |
| Cycle 5 Day 1 | 300 |
| Cycle 7 Day 1 | 252 |
| Cycle 9 Day 1 | 119 |
| Cycle 11 Day 1 | 96 |
| Cycle 13 Day 1 | 98 |
| Cycle 15 Day 1 | 96 |
| Cycle 17 Day 1 | 75 |
| Cycle 19 Day 1 | 56 |
| Cycle 21 Day 1 | 96 |
| Cycle 23 Day 1 | 60 |
| Cycle 25 Day 1 | 60 |
| **Cycle 27 Day 1** | **25** |










| | | | |
|---|---|---|---|
| Longest Axis | **19** | **12** | **05** |
| Perpendicular Measurement | **15** | **05** | **05** |
| Product of Perpendicular Diameters | **285** | **60** | **25** |

# Vebreltinib – Additional Indications

- EGFR resistance & c-Met amplification
- Other solid tumors with c-Met alterations, beyond lung & brain
  - Gastrointestinal cancers: colon, stomach, pancreatic, liver, cholangiocarcinoma
  - Renal cell cancer
  - Thyroid cancer
  - Prostate cancer
  - Breast cancer
  - Ovarian, and other female reproductive tract

# Uproleselan (APL-106) seeks to address $1.4B market for AML

## AML



**29,400 incidence in China***

## $1.4B total AML market opportunity in China**

Acute Myeloid Leukemia

| | |
|---|---|
| • 1L treatment naïve AML | **~ 16,400 patients*** |
| • Relapsed refractory AML | **~ 12,600 patients*** |
| • AML patients unfit for chemotherapy | **~ 8,800, patients*** |

Source: *IQVIA Market Research;
**management estimates for China Market arrived at using patient numbers and average price estimated by IQVIA

# Uproleselan (APL-106) First-In-Class E-Selectin Antagonist

*Enhances efficacy of chemotherapy & reduces mucositis (from chemotherapy)*




Source: GlycoMimetics

- Prevents trafficking of tumor cells to the bone marrow
- Disrupts cell adhesion-mediated drug resistance (CAMDR) within bone marrow microenvironment
- Inhibits activation of cancer survival pathways (e.g. NF-kB)
- Protects normal HSCs through quiescence enhancement and ability for self-renewal
- Reduces chemotherapy-associated toxicity (e.g. severe mucositis)
- 2nd generation GMI-1678 (APL 108) has equivalent activity to APL-106 in preclinical studies, but at an approximately 1,000-fold lower dose

# APL-106 Phase 3 Clinical trials in AML with near term readouts

*E-Selectin Inhibitor: first-in-class*




## Uproleselan (APL-106)

***AML- Phase 3 in China***

- ✓ FDA & NMPA Breakthrough Therapy Designations
- ✓ FDA Fast Track Designation

✓ AML: Significant clinical unmet needs –
high relapse rate, low survival rate

- Phase 1 /2
  - Efficacy: Impressive CR/CRi, MRD negativity, and overall survival in r/r & L1 AML
  - Safety: Well-tolerated; potential to ameliorate oral mucositis when combo w/ chemo
- r/r AML Phase 3 China Bridging, N=140 subjects
- r/r AML Phase 3 US/Global enrollment completed 2021, N~ 380 subjects
- 1L AML Phase 2/3 US: N up to 670 subjects

✓ APL-108 (higher potency, subcutaneous) for Multiple Myeloma and other solid tumors

✓ Strong IP protection for the compound and use in treating cancer and metastasis.

# Uproleselan (APL-106) Efficacy and Safety Data from US Phase 2 Trial

## Enhanced Efficacy

| | Relapsed / Refractory AML N=47 | Newly Diagnosed AML N=25 |
|---|---|---|
| Response Data: CR/CRi | 41% | 72% |
| Response Data: MRD Negative Rates | 69% | 56% |
| Survival Outcomes | Median Overall Survival (OS): **8.8** Months | Median Event Free Survival (EFS): **9.2** Months<br>Median Overall Survival (OS): **12.6** Months |

## Improved Tolerability to Chemotherapy – oral mucositis

DeAngelo et al Blood Feb 2022

# Uproleselan (APL-106) Global Clinical Programs in Acute Myeloid Leukemia

## GlycoMimetics Global Studies

- GMI-Sponsored Global Phase 3 trial in r/r AML; FULLY ENROLLED
- NCI-Sponsored Trial in Newly Diagnosed AML "Fit" for Chemo; Target interim analysis 2022
- UC Davis IST - Newly Diagnosed AML "Unfit" for Chemo; combo with venetoclax + azacytidine; N=25 subjects

## Apollomics China Studies

- Phase 1 PK Study (N=12 subjects; ongoing)
- Phase 3 Bridging Study in r/r AML (ongoing)

# Pipeline of Early Clinical and Preclinical Programs



# APL-122: Potent panERB Inhibitor Overcomes Treatment-Resistance In Solid Tumors & Crosses BBB to Address Brain Metastases

**APL-122 Effective In Treatment-resistant gastric cancer (HER2+) N87 xenograft**




**APL-122 Effective In Treatment-resistant NSCLC (T790M+) H1975 xenograft**




**APL-122 enters brain and is retained in CNS at higher than plasma levels**




- ErbB/HER crosstalk correlated with anti-ErbB therapy resistance
- APL-122- Inhibition of multiple ErbB family members to overcome resistance
- APL-122 & c-Met inhibitor combo may further limit drug resistance because HER2 amp+ and MET amp+ are mechanisms of acquired resistance

- 50% of HER2+ breast cancer and more than 33% of EGFR+ NSCLC develop CNS progression

Frentzas et al. Society of NeuroOncology Annual Meeting 2021

# APL-102: Potent Multitargeted kinase inhibitor against VEGFR1/2/3, b/cRAF, CSF1R, KIT, RET in Solid Tumors

- Unique kinase profile with inhibition of several other key **immuno-oncogenic drivers**
- Tumor regression in 52 PDX models, including gastric, colorectal, esophageal, and lung cancer
- HCC PDX model: APL-102 achieved larger reduction in tumor volume
- Phase 1 study – ongoing

## Superior Efficacy to Sorafenib in Liver Cancer

**HCC model PLC-PRF-5**




**HCC PDX model LIMsh050**




## Tumor Regressions In 52 PDX Models




Kanekal et al. American Association of Cancer Research Annual Meeting 2018

# Near-term Catalysts

## 2023

***Anticipated closing of deSPAC transaction***

***APL-101***
- Potential for US NDA submission for Exon 14 NSCLC
- Data readout of c-Met Amp+ NSCLC
- Data readout of Phase 2/3 GBM with MET fusion

***APL-106***
- Complete Phase 1
- Global AML Phase 3 readout

***APL-108***
- File IND and begin phase 1 study in China

## 2024

***APL-101***
- Launch commercially in US
- File first sNDA

***APL-106***
- China Phase 3 readout
- Submit NDA in China for treatment of r/r AML

***APL-801 and APL-810***
- File INDs

***APL-102 and APL-122***
- Phase 1 readout
- Phase 2 advancement

## 2025

***APL-101***
- Second sNDA submission
- Expand commercial in US

***APL-106***
- Commercial launch for r/r/ AML
- sNDA submission in treatment naïve AML

***APL-102 and APL-122***
- Phase 2 readouts

***APL-801 and APL-810***
- Complete Phase 1 and readout

apollomics